QStat Cartridge in Obstetric Patients
Launched by HEMOSONICS LLC · Feb 4, 2024
Trial Information
Current as of July 22, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The Quantra System is a fully integrated and automated in vitro diagnostic device which uses SEER Sonorheometry, an ultrasound-based technology, to characterize the viscoelastic properties of a whole blood sample during coagulation. The QStat Cartridge was developed to monitor hemostasis in patients that may experience a range of coagulopathies of various etiologies including fibrinolytic defects. These patients include the tobstetric hemorrhage population. The cartridge consists of four independent channels each containing different sets of reagents, which provide four measurements perform...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Subject is greater than18 years.
- • Subject is pregnant or at least 24 h postpartum
- • Conventional coagulation tests and/or viscoelastic testing are ordered for concern of possible coagulopathy based on one or more clinical scenarios including hemorrhage, suspected or confirmed placental abruption, amniotic fluid embolism, or placenta accreta spectrum
- • Subject or subject's LAR is willing to provide informed consent, either prospectively or by deferred consent.
- Exclusion Criteria:
- • Subject is younger than 18 years old.
- • Subject or subject's LAR is unwilling or unable to provide informed consent, either prospectively or by deferred consent.
- • Subject is incarcerated at the time of the study.
- • Subject is currently enrolled in a distinct study that might confound the results of the proposed study
- • Subject is affected by a condition that, in the opinion of the clinical team, may pose additional risks
About Hemosonics Llc
Hemosonics LLC is a pioneering biotechnology company focused on advancing diagnostic solutions for the management of bleeding and clotting disorders. With a commitment to innovation, Hemosonics develops cutting-edge technologies that enable rapid and accurate assessment of hemostasis, empowering healthcare professionals to make informed clinical decisions. Through rigorous clinical trials and research initiatives, Hemosonics aims to enhance patient outcomes and improve the standard of care in critical care settings. The company is dedicated to fostering partnerships within the medical community to drive advancements in patient diagnostics and treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, New York, United States
Oklahoma City, Oklahoma, United States
Salt Lake City, Utah, United States
Pittsburgh, Pennsylvania, United States
Columbus, Ohio, United States
Dallas, Texas, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported